Merck to Hold Fourth-Quarter and Full-Year 2015 Sales and Earnings Conference Call on February 3

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Wednesday, Feb. 3. During the call, company executives will provide an overview of Merck’s performance for the quarter and full year.

Investors, journalists and the general public may access a live audio webcast of the call on Merck’s website at http://www.merck.com/investors/events-and-presentations/home.html. A replay of the webcast will be available at approximately 11:00 a.m. EST on Feb. 3 and will remain on the website for 12 months. The sales and earnings news release and supplemental financial disclosures also will be available in the Newsroom and Investor sections of the company’s website at www.merck.com.

Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 4404803. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 4404803. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call.

About Merck

Today's Merck is a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

View source version on businesswire.com: http://www.businesswire.com/news/home/20160105005012/en/

Merck
Media Contacts:
Lainie Keller, 908-236-5036
Steven Cragle, 908-740-1801
or
Investor Contacts:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Source: Merck

You May Also Be Interested In

• Serve Robotics (SBOT) Prices 10M Share Offering at $4/sh, Uplists to Nasdaq
• Nutriband (NTRB) Announces 2.1M Share Offering at $4/sh
• Growth isn't weak enough to truly undercut inflation pressures - BMO